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Abstract. Purified plasma membranes from normal rat liver, a rat hepatoma and a rat hepatic
fibrosarcoma have been shown to contain a protein which drastically inhibits avian
myeloblastosis virus reverse transcriptase activity. The inhibition is caused by the binding of 
the protein to the template. The binding and the consequent inhibition of enzyme activity are 
template-specific; copying of RNA templates is inhibited whilst that of DNA templates 
remains unaffected. Investigations using different templates suggest that the inhibitory 
protein has a stronger binding affinity for G, C-rich templates. The inhibitor appears to have a 
wide distribution in plasma membranes from diverse sources.
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Introduction 
 
During the course of a study of the role of host factors in the infection of cells by
retroviruses, we have isolated and partially purified a 120,000 dalton protein from
plasma membranes of chicken embryonic cells. This protein causes a four-fold
stimulation of reverse transcriptase activity (Padhy et al., 1976; Das et al., 1978).
We have also reported the presence of an inhibitory activity to reverse transcrip- 
tase in plasma membrane preparations from chicken embryonic cells (Das et al., 
1978). An examination of plasma membrane preparations from non-embryonic 
sources such as rat liver, a rat hepatoma (Zajdela ascitic hepatoma, ZAH) and a rat 
hepatic fibrosarcoma (Yoshida ascitic fibrosarcoma, YAS) has now shown that 
although no stimulatory factor is present in plasma membranes from these sources, 
there is a strong inhibitory activity in both normal and tumor plasma membranes. 
We report here the identification and characterization of this activity, and 
demonstrate that the inhibition is brought about by the binding of the inhibitor to 
the RNA template.
 
Materials and methods 
 
Unlabelled deoxynucleoside triphosphates and synthetic templates were obtained 
from PL Biochemicals. (Me-3H)-TTP (56 Ci/mmol) and (3H)-dGTP (8 Ci/ 
 
 
Abbreviations used: ZAH, Zajdela ascitic hepatoma; YAS, Yoshida ascitic fibrosarcoma; AMV, avian 
myeloblastosis virus. 
 
107 
108 Parnaik et al. 
 
mmol) were obtained from Amersham-Searle, and calf thymus DNA and bovine 
serum albumin were purchased from Sigma Chemical Co., St. Louis, Missouri, 
USA. Chemicals for enzyme assays were obtained from Patel Chest Institute, New 
Delhi. All other chemicals were of analytical grade. Purified avian myeloblastosis 
virus (AMV) reverse transcriptase was a gift from  Dr  J.  W.  Beard,  Life  Sciences  
Building, St. Petersburg, Florida, USA.
 
Tumor cells: Zajdela ascitic hepatoma (ΖAH) and Yoshida ascitic fibrosarcoma 
(YAS) cells were maintained by serial transplantation of the tumor in Wistar rats. 
ZAH cells were obtained from Dr. F. Zajdela, Institut du Radium, Orsay, France 
and YAS cells were obtained from Cancer Research Institute, Parel, Bombay.
 
Plasma membrane preparation: Plasma membranes were prepared by three 
different methods as described elsewhere (Ray, 1970; Aaronson and Touster, 
1972; Lesco et al., 1973). 
 
Isolation of AMV-RNA: AMV-RNA was isolated from purified AMV using 
phenol-cresol extraction as described earlier (Das and Mink, 1979).
 
Enzyme assays: Reverse transcriptase was assayed as described earlier (Parnaik and
Das, 1981). 5'-Nucleotidase (Gurd and Evans, 1974), succinic dehydrogenase
(Earl and Korner, 1965), alkaline phosphatase (Pekarthy et al., 1972), alkaline
phosphodiesterase I (Pekarthy et al., 1972), inorganic pyrophosphatase (Shatton et 
al., 1981) and glucose-6-phosphatase (Swason, 1955) were assayed as described.
 
Protein estimation: Protein concentrations were estimated by a modification of 
Lowry's method (Lowry et al., 1951). Membrane suspensions (0.25 ml) were
added to 1 ml alkaline tartarate solution (0.2% Na, Κ tartarate, 2% sodium 
carbonate and 0.002% cupric sulfate in 0.1M NaOH) and incubated at room 
temperature for 20 min. SDS (0.1 ml, 0.5%), and Folin's reagent (0.1 ml 2N) were 
then added in quick succession, and the mixture was vortexed. Absorbance at 740 
nm was measured after keeping the samples at room temperature for 30 min. 
Bovine serum albumin solutions of known concentrations were used as standards. 
 
 
Results 
 
Inhibition of reverse transcriptase 
 
Plasma membranes from normal rat liver, ZAH and YAS cells were isolated and 
assayed for purity by determining the enrichment of marker enzymes. Plasma 
membrane markers (5'-nucleotidase, alkaline phosphodiesterase I and alkaline 
phosphatase) were enriched 10-20 fold, whereas cytoplasmic contaminants 
(succinic dehydrogenase, inorganic pyrophosphatase and glucose-6- 
phosphatase) were undetectable. The membrane preparations were solubilized in 
1% NP-40 and added to reverse transcriptase reaction mixtures. The final 
concentration of NP-40 was adjusted to 0.5% in the reaction mixtures. The 
concentration of membrane preparations ranged from 0.1 to 0.5 mg/ml according 
to the requirement of the experiments and are shown in the legends to tables and 
figures for individual experiments. Membrane preparations from normal liver as 
well as ZAH and YAS cells inhibited the copying of ploy rA.oligo dT by reverse 
transcriptase (figure 1). The drastic inhibition by liver plasma membranes was 
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Figure 1. Reaction mixtures containing enzyme (0.72 U), 0.1 ml of solubilised plasma
membranes in 1% NP-40 (30 µg of total protein) and components of the assay mixture (with
poly rA.Oligo dT as template) in a total volume of 0.2 ml were incubated at 37°C. Aliquots (25
µl) were removed at various time intervals and assayed for reverse transcriptase activity as 
described in Methods. (?) Enzyme alone (in 1% NP-40); (▲) enzyme and liver plasma
membrane; (∆) enzyme and ZAH plasma membranes; (O) enzyme and YAS plasma
membranes;(?)liver plasma membranes and enzyme in presence of 0.02 mM cysteine. ZAH
plasma membranes and enzyme in presence of 0.02 mM cysteine showed the same kinetics as
ZAH plasma membranes and enzyme in the absence of cysteine. 
 
partly due to high levels of alkaline phosphatase activity in the plasma membrane 
preparations, as shown later. Due to this interfering inhibitory activity in liver 
plasma membrane preparations, most of the studies on the mechanism of 
inhibition were performed with tumor plasma membranes. As shown in figure 2, 
the inhibition was a linear function of the plasma membrane concentration, 
indicating that the inhibition ‘was specific. The inhibitory activity was non- 
dialysable, suggesting that it was macromolecular in nature. 
 
In order to determine whether the inhibitor was a protein, the plasma membrane
preparations were treated with trypsin, followed by the addition of soybean trypsin 
inhibitor to inactivate trypsin, and then assayed for inhibition of reverse 
transcriptase. The inhibitory activity was destroyed by treatment with trypsin, 
indicating that the inhibitor is a protein (see table 1). Furthermore, inhibitory 
activity was abolished by incubating the solubilized membranes at 80°C for 5 min. 
 
The possibility that the inhibition could also arise from the presence of any
endogenous RNA or DNA in plasma membrane preparations that would 
competitively bind to the enzyme and inhibit poly rA.oligo dT copying was ruled 
out in the following manner. Membrane preparations were assayed for their ability 
to support DNA synthesis by reverse transcriptase by the addition of purified 
membranes (in 0.5% NP-40) to assay mixtures containing enzyme, all four dNTPs 
and oligo dT as primer but no other added template. Under these circumstances no 
 
110 Parnaik et al.
 
 
Figure 2.  Enzyme samples (0.72 U) were treated with different concentrations of ZAH
plasma membranes in 1% NP-40 (0.1 to 0.5 mg/ml) and assayed for activity (with poly
rA.oligo dT as template) after 20 min at 37°C as described in Methods.
 
Table 1. Effect of trypsin treatment on the plasma membrane inhibitor. 
 
ZAH plasma membranes (20 µg in 0.5% NP-40) were treated with 1 mg trypsin for 20 min. at 
37°C, followed by the addition of 3 mg of soybean trypsin inhibitor. After 20 min. at 37°C, 1.0 
U of reverse transcriptase and other components of the assay were added to give a total 
volume of 0.15 ml, and activity was determined as described in Methods. A control reaction 
with 0.5% NP-40 in the absence of plasma membranes was carried out in an identical manner. 
Values for control reactions in the absence of trypsin and SBTI treatment are also indicated. 
The specific activity of 3H-TTP used was 500 cpm/pmol. 
 
DNA synthesis was evident. The data strongly suggests that the inhibition is
specifically brought about by a plasma membrane protein. The inhibitory activity
was reproducibly observed from several batches of plasma membrane
preparations, isolated by different methods and stored over varying lengths of
time. 
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A series of experiments were carried out to test whether the observed inhibition
could arise from the presence of any protease or nuclease activities in the 
membrane preparations. These were ruled out (results not shown). Protease 
activity was checked by the Kunitz method (Kunitz, 1947), using standard casein 
solutions. Ribonuclease and polynucleotide phosphorylase activities were assayed 
using Escherichia coli total RNA as substrate. Any interfering deoxyribonuclease 
activity in the membrane preparations was ruled out by the absence of degradation 
of DNA in incubation mixtures containing added DNA and membrane samples 
(results not shown). 
 
As indicated earlier, liver plasma membranes contained considerable amounts
of alkaline phosphatase, whereas tumor plasma membranes contained much lower
amounts. In order to determine whether inhibition of reverse transcriptase by the
membrane preparations was due to alkaline phosphatase activity, assays were
carried out in the presence of 0.02 mM cysteine, a known inhibitor of alkaline
phosphatase. Under these conditions, there was no effect on inhibition of reverse 
transcriptase by tumor membranes. However, the level of inhibition by liver 
plasma membranes decreased to the level of inhibition by tumor plasma 
membranes. It is clear from these experiments that whereas there was a genuine 
inhibition of reverse transcriptase by normal and tumor plasma membranes, the 
difference in the levels of inhibition by different membranes was due to differences 
in alkaline phosphatase levels in the membrane preparations. In order to check the 
presence of other phosphatases in membrane preparations, membranes were 
incubated with dNTPs. Under these conditions no degradation of dNTPs was 
observed. 
 
We conclude from these experiments that the inhibition of reverse transcriptase
by the membrane preparations is not caused by ribonuclease deoxyribonuclease,
protease or phosphatase activities present in the membranes, but is caused by a 
specific protein inhibitor. 
 
Mechanism of inihibition 
 
The binding of the inhibitor either to the template or the enzyme could result in the 
observed decrease in DNA synthesis by reverse transcriptase in presence of 
plasma membrane preparations. If the inhibition is caused by the binding of the 
inhibitor to the enzyme, then at limiting concentrations of the inhibitor, increase in 
enzyme concentration should relieve inhibition. However, it was observed that as 
the enzyme concentration was increased five-fold, the percentage of inhibition did 
not vary significantly, indicating that the decrease in DNA synthesis was 
independent of enzyme concentration.
 
In order to determine whether the inhibitor acts by binding to the nucleic acid
template, the effect of increasing template concentration on the extent of inhibition 
was studied. At limiting concentrations of the inhibitor, an increase in template 
concentration should relieve inhibition if the inhibitor acts by binding to the 
template. As shown in figure 3, inhibition is relieved considerably as the template 
concentration is increased. This observation strongly suggests that the inhibitor 
acts by binding specifically to the nucleic acid template.
112 Parnaik et al. 
 
Figure 3. ZAH plasma membranes (10 µg) were added to reaction mixtures containing 
enzyme (0.24 U), various concentrations of poly rA.oligo dT (4-120 µg/ml) and the rest of the 
assay components in a volume of 0.1 ml. Enzyme activity was assayed after 10 min. at 37°C as 
described in Methods. Control reactions in the absence of membranes were carried out in an 
identical manner at each template concentration. 
 
 
Template-specificity of inhibitor 
 
The binding of the inhibitor to nucleic acid templates was critically examined using
different templates. It can be seen from table 2 that the plasma membrane inhibitor
specifically inhibits the copying of RNA templates including native AMV RNA,
and has no detectable effect on the copying of two DNA templates: poly dA.oligo
 
Table 2. Template specificity of inhibitor.
 
Enzyme samples (0.1-2.0 U) were assayed with different templates (20 µg/ml) in the
presence of 20 µg ZAH plasma membranes in a total volume of 0.1 ml. Enzyme activity was
determined after 30 min. at 37°C as described in Methods. The specific activity of 3H-dNTP
(500-5000 cpm/pmol) was varied to give optimum incorporation of radio-activity for the
different templates. 
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dT and activated calf thumus DNA. Furthermore, inhibition is considerably higher 
with the G, C-containing template, poly rC.oligo dG, suggesting that the inhibitor 
has a stronger binding affinity for G,C residues. 
 
Experiments were also carried out to check whether the inhibitor specifically 
affects chain initiation. Rates of DNA synthesis were measured for two sets of 
parallel assays. In one set, reactions were started by the simultaneous addition of 
the enzyme and inhibitor to assay mixtures containing all the components of the 
reaction except the enzyme. In the second set, reactions were allowed to proceed
for 5 min by adding aliquots of enzyme alone to the assay mixtures. At this point
samples of membrane preparations were added to the reaction mixtures in this set.
Both sets of reaction mixtures were incubated at 37°C and the incorporation of
labelled TTP was monitored upto 40 min. The results showed no difference in the
rates of incorporation of label between the two sets (data not shown). The absence
of enhanced inhibition in reactions in which the inhibitor was present at start rules
out the possibility of specific inhibition during the chain initiation event.
 
 
Discussion 
 
A protein present in plasma membrane preparations from several sources such as 
normal liver cells, ZAH and YAS cells inhibits RNA-directed DNA synthesis by 
reverse transcriptase. Our results suggest that a template-inhibitor interaction is 
responsible for the observed inhibition. The inhibitor interacts specifically with 
RNA templates, and has a stronger affinity for G, C-containing polynucleotides. 
Preliminary experiments suggest that the inhibitor is present in membrane 
preparations from several other sources such as chicken liver cells and neonatal 
mouse liver cells. Recently, inhibitors of reverse transcriptase have been detected 
in mouse spleen cells (Rokutanda et al., 1982) and human placental tissue (Nelson 
et al., 1981). However, the cytoplasmic origin of both inhibitors makes it unlikely
that they are similar to the inhibitor we have identified in plasma membranes.
 
The presence of an RNA-binding protein in plasma membranes from diverse
sources raises the question of the functional role of such a molecule. Since
replication of the retroviral genome proceeds via an RNA-dependent DNA
polymerization, the inhibitory role of an RNA-binding protein could, in principle, 
provide a protective mechanism for the host. It has also been suggested that RNA- 
binding proteins might be involved in such diverse phenomena as the induction of 
interferons by double-stranded RNA molecules (Gordon and Hinks, 1981), 
modulation of host cell mRNA translation during infection by DNA tumor viruses 
(Khandjian et al., 1982), compartmentalization of cytoplasmic RNA (DeRobertis 
et al., 1982) and uptake of RNA by cells (Schell, 1971). It is not known whether 
these events take place at the cell surface or through the mediation of the plasma 
membranes. At present we do not know whether the RNA binding protein we have 
characterized in this study plays a role in any of these cellular events. Purification 
and further characterization of RNA-binding proteins from plasma membranes 
are under progress with a view to answer some of these questions.
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